<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231591</url>
  </required_header>
  <id_info>
    <org_study_id>19-005429</org_study_id>
    <nct_id>NCT04231591</nct_id>
  </id_info>
  <brief_title>NT-proBNP Levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients</brief_title>
  <acronym>NT-proBNP</acronym>
  <official_title>NT-proBNP Levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if NT-BNP levels obtained at time of admission for
      delivery are predictive of intrapartum or postpartum complications in patients with adult
      congenital heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amino-terminal pro-B-type natiuretic peptide (NT-proBNP) is a prohormone released from
      cardiac ventricular myocytes in direct response to cardiac workload. Secreted in the
      biologically inactive form, NT-proBNP is cleaved in the circulation into BNP, which
      subsequently exerts both vasodilatory and diuretic effects. The principal clinical utility of
      serum NT-proBNP measurement has been as an adjunctive marker in the diagnosis of subclinical
      heart failure, with higher levels typically reflective of increasing cardiac dysfunction.

      The proposed prospective cohort study intends to collect serum NT-proBNP levels in singleton
      ACHD patients and a comparative normotensive control group at time of admission for delivery
      to characterize negative predictive values for intrapartum and postpartum cardiac events.
      Both pregnant patients with previously-diagnosed ACHD and those diagnosed and delivering
      during the study interval will be candidates for participation, and a gestational age
      threshold of 37 weeks will be utilized for the control group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intrapartum cardiac complications</measure>
    <time_frame>Inpatient admission for subsequent 48 hours</time_frame>
    <description>Incidence of heart failure, incidence of arrhythmia, incidence of cardiac arrest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postpartum cardiac complications</measure>
    <time_frame>Initial 96 hours following delivery of infant(s)</time_frame>
    <description>Incidence of heart failure, incidence of arrhythmia, incidence of cardiac arrest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intrapartum obstetrical complications</measure>
    <time_frame>Inpatient admission for subsequent 48 hours</time_frame>
    <description>Incidence of preeclampsia or gestational hypertension, incidence of placental abruption, cesarean section rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum obstetrical complications</measure>
    <time_frame>Initial 96 hours following delivery of infant(s)</time_frame>
    <description>Incidence of postpartum hemorrhage, incidence of venous thromboembolism</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>ACDH Pregnancy - Study group</arm_group_label>
    <description>Pregnant women with known adult congenital heart disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncomplicated pregnancy - Control group</arm_group_label>
    <description>Healthy women with an uncomplicated pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NT-proBNP</intervention_name>
    <description>Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.</description>
    <arm_group_label>ACDH Pregnancy - Study group</arm_group_label>
    <arm_group_label>Uncomplicated pregnancy - Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study intends to collect serum NT-proBNP levels in singleton ACHD patients and a
        comparative normotensive control group at time of admission for delivery to characterize
        negative predictive values for intrapartum and postpartum cardiac events. Both pregnant
        patients with previously-diagnosed ACHD and those diagnosed and delivering during the study
        interval will be candidates for participation. A gestational age threshold of 37 weeks will
        be utilized for the control group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant adult women ages 18 - 50

          -  Pregnancy with congenital heart disease (study group) or without congenital heart
             disease (control group)

        Exclusion Criteria:

          -  Non-pregnant patients

          -  Non-English-speaking patients

          -  Maternal age &lt;18 years or &gt;50 years

          -  Patients with hypertensive complications of pregnancy

          -  Maternal peripartum cardiomyopathy

          -  Multiple gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl H. Rose, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather R LaBrec</last_name>
    <phone>507-293-3446</phone>
    <email>labrec.heather@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maureen A Lemens, BSN</last_name>
    <phone>507-293-1487</phone>
    <email>lemens.maureen@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather R LaBrec</last_name>
      <phone>507-293-3446</phone>
      <email>labrec.heather@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maureen A Lemens, BSN</last_name>
      <phone>507-293-1487</phone>
      <email>lemens.maureen@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Carl H. Rose</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

